SILVERARC CAPITAL MANAGEMENT, LLC
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 12, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$820.9M2026 Q3+ $33.5M options (notional, not included)
Positions70
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.52.0%
What Changed This Quarter?
Top Holdings
KOD
Kodiak Sciences
8.3%
CELC
Celcuity
7.5%
COGT
Cogent Biosciences
5.9%
URGN
UroGen Pharma
5.5%
IMNM
Immunome
5.3%
GLUE
Monte Rosa Therapeutics
4.3%
SGMT
Sagimet Biosciences
4.3%
ASND
Ascendis Pharma A/S
4.1%
New / Increased
18 new · 29 increased
CLDXNEW
Celldex Therapeutics
1.8%
Celldex Thera…CALLNEW
Celldex Therapeutics
1.4%
Rainier Acqui…NEW
Rainier Acquisition
1.0%
YARWNEW
Yarrow Bioscience
0.8%
ARCTNEW
Arcturus Therapeutics
0.7%
CELC
Celcuity
7.5%
+60.3%
GLUE
Monte Rosa Therapeutics
4.3%
+180.9%
KOD
Kodiak Sciences
8.3%
+37.3%
Reduced / Exited
20 reduced · 21 sold out
SNDX
Syndax Pharmaceuticals
0.5%
-79.6%
ELVN
Enliven Therapeutics
0.7%
-75.2%
DNTH
Dianthus Therapeutics
2.4%
-39.3%
PRAX
Praxis Precision Medicines
0.7%
-69.9%
ASND
Ascendis Pharma A/S
4.1%
-26.2%
Ark Etf TrPUTEXIT
Ark ETF Tr
2.2%
VCYTEXIT
Veracyte
1.9%
Syndax Pharma…CALLEXIT
Syndax Pharmaceuticals
1.6%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.